GSK Deal History & Licensing Activity
GSK is a large pharma headquartered in UK. Over the past three years, GSK has been involved in 15 licensing and acquisition transactions, with a primary focus on Small Molecules (7 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
8
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
GSK Recent Deal Activity
Licensing, acquisition, and partnership transactions involving GSK in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Trispecific T-cell engager | Chimagen | Bispecific Antibodies | Preclinical | acquisition | Sep 15, 2026 |
| Nuvalent pipeline (targeted kinase inhibitors for NSCLC) | Nuvalent, Inc. | Small Molecules | Phase 3 | acquisition | Jun 9, 2026 |
| alnodesertib + risvutatug rezetecan | Artios Pharma | Small Molecules | Phase 1 | collaboration | May 12, 2026 |
| bepirovirsen | SBP Group | Oligonucleotides | Approved | collaboration | May 11, 2026 |
| linerixibat | Alfasigma | Small Molecules | Phase 3 | license | Mar 10, 2026 |
| HS235 | 35Pharma | Small Molecules | Phase 1 | acquisition | Feb 25, 2026 |
| ozureprubart (zelorigotab / RPT193) and full RAPT Therapeutics pipeline | RAPT Therapeutics | Small Molecules | Phase 2 | acquisition | Jan 20, 2026 |
| antisense oligonucleotide (ASO) candidates | CAMP4 Therapeutics Corporation | Oligonucleotides | Discovery | collaboration | Dec 1, 2025 |
GSK Pipeline Focus
Therapeutic areas and modalities where GSK is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
GSK Strategic Signals
Key indicators of GSK's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
GSK Clinical Pipeline
GSK has 50 active clinical trials across 7 development phases.
2
Phase 4
1
Unknown
9
Phase 1
1
Phase 1/2
9
Phase 2
2
Phase 2/3
26
Phase 3
See How Your Asset Matches GSK's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About GSK Licensing & Deal Activity
GSK is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 15 deals over the past three years, GSK ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GSK include Solid Tumors (11 deals and trials), Gastroenterology (9 deals and trials), Infectious (9 deals and trials), and Oncology (8 deals and trials). In terms of modality, GSK has shown particular interest in small molecules, small molecules, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GSK and 700+ other biopharma companies. Use our Solidus to benchmark your asset against GSK's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.